Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 363 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 363 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $28.54, for a total value of $10,360.02. Following the sale, the insider now directly owns 83,945 shares in the company, valued at $2,395,790.30. The trade was a 0.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Apellis Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ:APLS opened at $27.40 on Friday. Apellis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $71.90. The stock has a market cap of $3.41 billion, a P/E ratio of -13.50 and a beta of 0.96. The business’s 50 day moving average is $31.21 and its 200 day moving average is $32.19. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Analyst Ratings Changes

Several equities research analysts have weighed in on APLS shares. The Goldman Sachs Group cut Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective on the stock. in a research note on Tuesday, December 17th. Piper Sandler reduced their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Citigroup cut their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Scotiabank cut their target price on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $26.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday, January 29th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $46.71.

Institutional Trading of Apellis Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its holdings in Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares during the period. AlphaCentric Advisors LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter worth $1,370,000. GSA Capital Partners LLP purchased a new stake in Apellis Pharmaceuticals during the third quarter worth $824,000. BNP Paribas Financial Markets lifted its holdings in Apellis Pharmaceuticals by 52.9% during the third quarter. BNP Paribas Financial Markets now owns 159,700 shares of the company’s stock worth $4,606,000 after buying an additional 55,282 shares during the period. Finally, Old West Investment Management LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter worth $2,953,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).